-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 28th Roche announced that NMPA had approved its Tecentriq joint Avastin (T-A joint program) for the treatment of patients with non-excisible hepatocellular carcinoma (HCC) who had not previously received systematic treatment.
the approval was based on the results of phase III clinical trial IMbrave150, which included an analysis of 194 Chinese sub-group patients.
results showed that Tecentriq-Avastin significantly extended the total survival of Chinese patients (immature vs. 11.4 months) as a first-line therapy, reducing the risk of death by 56% (HR s 0.44), while significantly extending patient PFS (5.7 vs 3.2 months) and reducing the risk of disease deterioration by 40% (HR s 0.60).
this data is consistent with the global data from the IMbrave 150 study.
safety, Tecentriq-Beval bead monoantin is generally well-resistant, toxic and consistent with known data.
primary liver cancer is the 4th most common malignant tumor and the 2nd cause of tumor death in China.
Chinese accounts for only 18.4% of the world's population, but each year new cases of liver cancer account for 55.4% of the world's total, and 53.9% of deaths worldwide, equivalent to more than 1,000 patients diagnosed with liver cancer every day, of which HCC accounts for 85% to 90%.
, the five-year survival rate of Chinese patients is only 12.2%, and people's lives and health are seriously threatened by liver cancer.
